Mechanism

Pharmacology

What the molecule does, from the moment you swallow it. Most of what makes a trip frightening has a plain mechanical explanation.

Psilocybin is a prodrug

Psilocybin itself is largely inactive. It is 4-phosphoryloxy-N,N-dimethyltryptamine, and the phosphate group is stripped off by alkaline phosphatase in the gut wall, liver and kidney to produce psilocin, which is the molecule that actually does something.

That conversion step is why oral onset takes twenty to sixty minutes rather than being immediate, and it is why lemon tek and hot tea shorten it: acid and heat hydrolyse some of the phosphate ester before it is ever swallowed, so a portion of the dose arrives already converted.

Psilocin is structurally close to serotonin. The difference is two methyl groups on the terminal nitrogen and the position of the hydroxyl. That similarity is the entire story. It is close enough to fit serotonin receptors, and different enough to behave differently once it is in one.

What it binds

5-HT2A: The receptor that matters. Psilocin is a partial agonist here, and this is where the psychedelic effect comes from. The proof is direct: pre-treating someone with ketanserin, a 5-HT2A antagonist, abolishes the subjective effects almost entirely while leaving the drug in their bloodstream.
5-HT2C: Also bound. Contributes to the nausea, the gut effects and some of the mood component.
5-HT1A: Bound with reasonable affinity. Appears to modulate anxiety, and may be part of why the experience is so sensitive to circumstances.
Dopamine receptors: Not meaningfully. This is worth stating because it is the pharmacological reason psilocybin has essentially no addiction liability. There is no direct reinforcement pathway of the kind stimulants and opioids act on.

What that does to the brain

5-HT2A receptors are dense on layer V pyramidal neurons in the cortex, cells that coordinate communication between brain regions. Agonism there increases their excitability, and the system-level result is a loosening of the usual segregation between networks that normally stay relatively separate.

The most reproduced imaging finding is reduced coherence within the default mode network, the set of regions associated with self-referential thought. The degree to which that network desynchronises correlates with how strongly people report the dissolution of ordinary self-reference. That is a real, mechanical explanation for the most striking thing about the experience, and it is unusual to have one.

Two cautions. Imaging correlations are not explanations, and the popular framing of psychedelics as “resetting” the brain runs considerably ahead of the evidence. What is established is that connectivity patterns change acutely. What that means for lasting change is still being worked out.

Metabolism and clearance

Psilocin is cleared two ways: glucuronidation by UGT enzymes, which accounts for most of it, and oxidation by monoamine oxidase A. Plasma psilocin peaks around eighty to a hundred minutes after an oral dose and has an elimination half-life of roughly two to three hours.

Two consequences follow. First, subjective effects track plasma psilocin closely, which is why the timeline is predictable enough for a countdown to be honest here in a way it would not be for most drugs. Second, the MAO-A route is exactly why MAO inhibitors amplify and extend the experience so dramatically, block that pathway and clearance slows unpredictably.

The timeline, and why it is that shape

Waiting

0–30 min

Nothing has started yet. Your stomach is still converting psilocybin to psilocin. That takes 20 to 60 minutes.

Coming up

30–90 min

Psilocin is entering your bloodstream and binding 5-HT2A receptors. Effects will keep building for about an hour.

Peak

90–180 min

Psilocin in your blood is at its highest. Normal communication between brain networks is loosened. This is the strongest it gets.

Coming down

180–300 min

Psilocin is clearing. Its half-life is about two to three hours, so the level in your blood is now roughly halving.

Afterglow

300–420 min

The main effects are over. What is left is tiredness, some residual mood change and a nervous system that has had a long day.

Toxicity

Psilocybin has one of the widest margins between an active dose and a lethal one of any known psychoactive drug. The estimated lethal dose is on the order of a thousand times a strong recreational one, which corresponds to several kilograms of dried mushrooms. There is no realistic route to fatal psilocybin toxicity by eating mushrooms.

The real risks are elsewhere, and they’re worth knowing:

Behavioural

Falls, traffic, water, heights. Almost every physical injury associated with psilocybin comes from impaired judgement in an ordinary environment, not from the drug's action on the body.

Cardiovascular

Psilocybin raises heart rate and blood pressure modestly. Irrelevant for most people; not irrelevant for someone with significant cardiac disease or an arrhythmia.

Psychiatric

Can precipitate or worsen psychosis in people with schizophrenia, or with a first-degree family history of it, and can trigger mania in bipolar disorder. This is the exclusion criterion every clinical trial uses.

Drug interactions

The lithium seizure signal is real and substantial. MAOIs amplify unpredictably. These are documented harms, unlike the frequently overstated SSRI serotonin syndrome risk.

HPPD

Hallucinogen persisting perception disorder, lasting visual disturbance after the drug has cleared. Genuinely rare, poorly understood, and more often reported after repeated heavy use.

Lasting distress

A minority of people report a difficult experience that stays difficult for weeks. Survey data puts the rate of enduring negative effects at a small but non-zero percentage, and it correlates with dose and with being alone.